The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...

(NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: ...

In addressing the fourth-quarter figures for Eylea three weeks earlier at the J.P. Morgan Healthcare Conference, Regeneron had hoped to shift the focus of its quarterly call to positive news ...

During the last three months, 18 analysts shared their evaluations of Regeneron Pharmaceuticals REGN, revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of ...

Deep-pocketed investors have adopted a bullish approach towards Regeneron Pharmaceuticals (NASDAQ:REGN), and it's something market players shouldn't ignore. Our tracking of public options records ...